PCI Synthesis Celebrates Key Milestones Including 4th Consecutive Year of Double-Digit Growth, 2 Commercial Approvals and a New Office in San Diego

Has expanded into new markets, added new equipment, and won more awards

NEWBURYPORT, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEis), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, announced the company had hit key milestones at the start of 2018, which marks the company’s 20th anniversary as an operating entity.

The company just closed its fourth consecutive year-to-year of double-digit growth, driven by more than forty new customers and an expansion into new offerings such as GMP manufacturing for nutraceuticals and pharma foods, large-scale cryogenic manufacturing, large-scale chromatography, controlled substance development, and medical-grade polymers.

PCI Synthesis has won the “Top Performer” designation in all 14 categories of the 2017 CMO Leadership Awards from Life Science Leader Magazine, becoming North America’s most awarded drug substance manufacturer, with 24 CMO Leadership Awards since 2014.

PCI Synthesis, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as active pharmaceutical ingredients (APIs), secured two commercial approvals, bringing its total to 8 approved/pre-approved APIs in its overall pipeline. This is the fourth consecutive year the company has received approvals for one or more products and continues to demonstrate the maturation of a pipeline of drug products that began in 2012 and has more than 15 API and other advanced materials products in its pipeline.  

“The company has pivoted several times over the last two decades, enabling us to reach major milestones with customers, products, staff and awards, testament to the quality of our work and our commitment to put the customers first. In that time, we’ve been able to grow and expand and deliver new services and products to our customers,” said Ed Price, president of PCI Synthesis and a new member of the board of governors of the Society of Chemical Manufacturers and Affiliates (SOCMA). “We continue to develop scientific advances, such as our recent filing to patent an innovative process to synthesize Azelaic Acid, which is used as a drug substance for skin-care therapeutics.”

Additionally, the company also expanded into the west coast with the opening of a San Diego office staffed by business development manager, Scott VanderWall. PCI Synthesis now has more than 120 employees working at three locations: Newburyport and Devens, MA and San Diego; the company has more than doubled in size over the last four years. The company and its employees are also active in their communities, supporting organizations like Opportunity Works, Toys for Tots and The Community Service of Newburyport.

About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry.  As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.

Linda Pendergast-Savage
Birnbach Communications